RNS Number:0663T
Antisoma PLC
10 December 2003

                           Board changes at Antisoma



10 December 2003, London, UK (LSE: ASM) - Antisoma plc, the UK-based
biopharmaceutical company specialising in the development of products for the
treatment of cancer, today announces the appointment of Birgit S. Norinder as a
non-executive Director with immediate effect.  Mrs Norinder succeeds Dr James
Coombes, who retired from the Antisoma Board at the conclusion of the Annual
General Meeting of Shareholders on 9 December 2003.



Mrs Norinder has served as Chairman and CEO of Prolifix Ltd, a biotechnology
company focusing on oncology, and currently serves on the Boards of a number of
biotechnology companies, including two listed companies, PhotoCure ASA of Norway
and Probi AB of Sweden. She was previously a Director of Araccel AB (now MiniDoc
AB).



Mrs Norinder is a trained pharmacist and has held senior executive positions in
R&D in a number of international pharmaceutical companies, including Pharmacia &
Upjohn Corp, where she was Senior Vice President Worldwide Product Development,
Glaxo Group Research Ltd, where she was Director of the International Regulatory
Affairs Division, and Astra Research Centre AB, where she was Vice President,
Infection R&D. She has also held positions at Pfizer Inc and at Parke Davis AB.



With regard to Mrs Norinder's appointment, there are no disclosures required
under paragraph 6.F.2 (b)-(g) of the Listing Rules of the U.K. Listing
Authority.



Barry Price, Chairman of Antisoma, said: "Birgit has a wealth of experience from
the biotech and pharmaceuticals sector, and will provide valuable insight as we
enter the next phase of the Company's development.  I would like to thank Jim
Coombes sincerely for his valuable contribution to Antisoma over the last six
years."



Enquiries:
Glyn Edwards, Chief Executive Officer                    Tel: +44 (0)20 8799 8200


Ben Atwell/Sarah Macleod, Financial Dynamics             Tel: +44 (0)20 7831 3113



About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma formed a broad strategic alliance with Roche to develop and
commercialise products from Antisoma's pipeline. Please visit www.antisoma.com
for further information about Antisoma.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOADKLFBXLBZFBE